Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 55Carcinoma, Hepatocellular 54Lung Neoplasms 32Small Cell Lung Carcinoma 28Neoplasms 25Breast Neoplasms 20Colorectal Neoplasms 18Melanoma 15Triple Negative Breast Neoplasms 14Urinary Bladder Neoplasms 13Carcinoma, Transitional Cell 13Neoplasm Metastasis 12Carcinoma, Renal Cell 12Squamous Cell Carcinoma of Head and Neck 10Prostatic Neoplasms 9Uterine Cervical Neoplasms 8Stomach Neoplasms 8Glioblastoma 8Endometrial Neoplasms 7Ovarian Neoplasms 6Head and Neck Neoplasms 6Sarcoma 5Pancreatic Neoplasms 5Carcinoma, Neuroendocrine 5Carcinoma, Merkel Cell 5Liver Neoplasms 4Kidney Neoplasms 4Extensive Stage Lung Small Cell Carcinoma 4Carcinoma 4Brain Neoplasms 4

Interventions

tucatinib 1pertuzumab 1atezolizumab 1Trastuzumab 1Fulvestrant 1Alpelisib 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Metastatic Breast Cancer × atezolizumab × 1 year × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡